NHS access to Wegovy and Mounjaro: what NICE recommends
NICE has recommended both medicines for weight management on the NHS under conditions, and the NHS is introducing tirzepatide in phases. What the guidance says, and why eligibility is a decision for the NHS, not this site.
The price table on The Dose Club lists private prices. Both medicines are also available through the NHS, under conditions set by the National Institute for Health and Care Excellence (NICE) and arrangements made by the NHS. This article describes the shape of those arrangements. Whether you qualify is a decision for the NHS clinicians who assess you, and nothing on this site can tell you the answer.
A licence is not the same as NHS funding
The MHRA decides whether a medicine can be marketed in the UK by granting a marketing authorisation. NICE decides separately whether the NHS should fund it and for whom, through a technology appraisal. NICE technology appraisal guidance applies in England and Wales; Scotland has its own body, the Scottish Medicines Consortium, and Northern Ireland reviews NICE guidance for local use. A medicine can be licensed and sold privately without NICE having recommended it for the NHS, and a NICE recommendation can be narrower than the licence.
Semaglutide (Wegovy): technology appraisal TA875
NICE guidance TA875 recommends semaglutide as an option for weight management, alongside a reduced calorie diet and increased physical activity, in adults who meet conditions set out in the guidance. The conditions include a body mass index threshold combined with at least one weight related health condition, or a lower threshold for people who meet the criteria for referral to a specialist weight management service. The guidance says it should be used within a specialist weight management service and for a maximum of two years, and that lower BMI thresholds should be used for people from some ethnic backgrounds, which it names.
Tirzepatide (Mounjaro): technology appraisal TA1026
NICE guidance TA1026 recommends tirzepatide as an option for managing overweight and obesity, alongside a reduced calorie diet and increased physical activity, in adults who meet a body mass index threshold and have at least one weight related health condition, again with lower thresholds for people from some ethnic backgrounds. The guidance also carries a funding variation, so tirzepatide is being introduced in phases and the recommendation does not mean everyone who meets the conditions is offered it at once. NHS England's interim commissioning guidance sets out who is eligible in each phase, by body mass index and number of weight related health conditions, starting with the groups it judges to have the greatest clinical need.
How access works in practice
- Your GP practice is the starting point for a conversation about weight management on the NHS. The NHS website says these medicines are usually prescribed alongside diet and lifestyle advice, and that after you stop taking them you should be offered support to stay a healthy weight.
- Semaglutide on the NHS is prescribed through specialist weight management services, which GPs refer into.
- Tirzepatide is being introduced in phases, through GP practices and specialist services, according to NHS England's arrangements.
- NHS prescriptions carry the standard prescription charge in England and are free in Scotland, Wales and Northern Ireland.
Why this site says nothing about your eligibility
The Dose Club is a price comparison, a tracker and a community. It does not assess anyone. The NICE criteria are applied by clinicians with your records in front of them, and local NHS arrangements decide how quickly a phase reaches you. A private prescription and an NHS prescription are for the same licensed medicines, dispensed with the same leaflets, so the leaflet based articles on this site apply either way. The price table applies only to the private route.
If you move between the two
People do move from a private prescription to an NHS one, or the other way. Both prescribers need to know what you have been taking and for how long. The Dose Club app's prescriber PDF, in Dose Club Plus, puts your logged doses, weights and symptoms in one document for that conversation.
Sources
- NICE technology appraisal TA875, Semaglutide for managing overweight and obesity, and TA1026, Tirzepatide for managing overweight and obesity: nice.org.uk
- NHS, treatment for obesity: nhs.uk
- MHRA, marketing authorisations: gov.uk
This article is information, not medical advice. Talk to your prescriber about your treatment.
- NHS
- NICE
- access